SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending due to a strategic partnership with Crypto.com to launch an exclusive U.S. prediction markets platform, coupled with plans for sports betting expansion. The community is actively discussing the stock's significant surge, high volume, and potential for a short squeeze given its low float. However, some are also debating the possibility of future share offerings amidst the intense market activity.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending sharply following a stellar earnings report that surpassed expectations with strong margins and aggressive capital expenditure plans, driven by persistent AI chip demand. The community is actively discussing the CEO's "AI megatrend" outlook, interpreting the results as a significant bullish indicator for the entire semiconductor sector. This strong performance is expected to generate positive momentum for related companies in the AI supply chain.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is experiencing an intense surge of conversation following its Q3 financial report release, which arrived significantly ahead of its NASDAQ compliance deadline and indicated a strong return to profitability. The news has ignited fervent discussions among traders, who are anticipating a major short and gamma squeeze due to high short interest and renewed confidence as delisting fears subside. The community is actively debating the potential for a substantial upward movement, with many drawing parallels to historical market squeezes like CVNA or GME.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently a focal point for investors, navigating ongoing Wall Street downgrades alongside intense discussion around a potential credit card interest rate cap and its implications for the company's Buy Now Pay Later services. Despite significant community frustration regarding recent stock performance and calls for leadership changes, many perceive PYPL as fundamentally undervalued, citing robust financials and strategic AI partnerships. This creates a deeply divided sentiment, with some confidently calling a bottom while others anticipate further price erosion amid concerns of market manipulation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing a surge due to intensified geopolitical focus on Greenland's vast critical mineral resources, highlighted by the formation of a U.S., Denmark, and Greenland working group on security and resource development. Community discussion is buzzing with expectations of significant U.S. investment and supply chain security, fueling heavy trading volume and speculation about a potential short squeeze for the company. This dynamic positions CRML as a central player in the global race for essential rare earth elements.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with renewed investor interest, fueled by Cantor Fitzgerald's reiterated "Overweight" rating and $18 price target, ahead of its J.P. Morgan Healthcare Conference presentation. The community is buzzing with speculation about new Matrix-M platform partnerships, particularly in the oncology sector, and the potential for a significant short squeeze given the high short interest. This optimism is tempered by ongoing shareholder frustration regarding management's execution and hopes for strategic changes, including a potential proxy fight.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending sharply higher, propelled by robust sentiment across the semiconductor industry amid encouraging economic data and positive earnings reports from key players like TSMC. The community is actively debating its substantial rally, with many anticipating continued upside driven by insatiable AI demand, while others signal caution about an "AI bubble" and potential for profit-taking given its leveraged nature. Upcoming tech conferences, such as CES, further highlight the sector's pivotal role in technological advancements.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending following several positive analyst upgrades and a recent earnings beat, which showcased strong free cash flow and a diversified multi-basin portfolio. The community is actively discussing DVN's attractive valuation, strategic acquisitions, and efforts to enhance shareholder returns, with growing interest in its potential to leverage natural gas and geothermal for powering AI data centers.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amidst reports that Sanofi is preparing an improved takeover bid after its initial offer was rejected, sparking community discussions about a potential bidding war. This acquisition interest coincides with high anticipation for the upcoming SOL-1 Phase 3 trial data for AXPAXLI, expected in Q1 2026, which many believe could significantly re-rate the company. Investors are closely watching, noting institutional accumulation and the potential for the long-acting wet AMD therapy to reshape the market.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing heightened investor interest and significant trading volume, fueled by speculation of a gamma squeeze driven by expiring call options and community enthusiasm for its Optical Interposer technology. This core innovation for high-speed, energy-efficient AI data center interconnects is generating strong anticipation for upcoming news on strategic partnerships and product developments, despite reports of some online brokers restricting buy orders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx (NASDAQ:ARDX) Stock Price Down 6.8% on Insider Selling

Ardelyx (NASDAQ:ARDX) Stock Price Down 6.8% Following Insider Selling...

Are Medical Stocks Lagging  Ardelyx (ARDX) This Year?

Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells 50,000 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura Williams sold 50,000 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an...

<ul class="summary-bullets"><li>Piper upgraded Ardelyx to ‘Overweight’ and lifted its price target to $16 after sharply higher 2026 guidance.</li><li>The company now expects its lead therapy to reach $1 billion in annual revenue by 2029, years earlier than prior expectations.</li><li>Ardelyx also guided for continued growth across its broader portfolio, including Xphozah.</li></ul>Ardelyx shares&nbsp;rose nearly 3% in premarket trading on Friday after Piper Sandler upgraded the stock to ‘Overweight’ from ‘Neutral’, pointing to an improved revenue outlook for Ibsrela, the company’s first-in-class treatment for irritable bowel syndrome with constipation, following its latest guidance update.<h2 class="st-heading-2">Piper Upgrade Follows Guidance Reset</h2>Piper Sandler raised its Ardelyx price target to $16 from $10, implying an upside of about 130%, after the company updated its fourth quarter preliminary estimates and first fiscal 2026 guidance. The constipation drug “stole the show,” Piper Sandler wrote, referring to revenue projections that far exceeded expectations.The firm highlighted Ardelyx’s 2026 revenue guidance of $410 million to $430 million, which it said far exceeds consensus estimates of about $375 million. Piper also noted that the company now expects the treatment to reach $1 billion in annual revenue by 2029, roughly four years earlier than the firm had previously anticipated.<h2 class="st-heading-2">Constipation Drug Anchors Growth Outlook</h2>Ardelyx said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-stock-rallies-after-announcing-prelim-results-makes-retail-bullish/cmUbXbxR454">most of its 2026 revenue is expected to come from Ibsrela</a>. The company said revenue from the treatment is projected to rise at least 50% from 2025 levels.The drug is forecast to pull in roughly $274 million in revenue in 2025, which would be 73% growth versus 2024, the company said. Revenue in the fourth quarter was about $87 million, versus $53.8 million in the same period a year earlier.<h2 class="st-heading-2">Pipeline Progress</h2>In addition to its Ibsrela, Ardelyx estimated it will generate $110 million to $120 million in 2026 revenue from Xphozah, an FDA-approved drug that lowers phosphorus in adults with chronic kidney disease who receive dialysis.CEO Mike Raab said the company is entering 2026 “exceptionally well positioned” as it continues to invest in expanding its commercial footprint and long-term growth opportunities.Ardelyx also said a late-stage clinical trial evaluating its constipation drug in patients with chronic idiopathic constipation has begun and is expected to wrap up in the second half of 2027, a step that could broaden the drug’s potential market.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Ardelyx was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ardx_ss_png_7d339ba60e.webp" alt="ardx ss.png" width="972" height="148"><figcaption>ARDX sentiment and message volume as of January 9| Source: Stocktwits</figcaption></figure>One user said the next potential target could be around $7.50, pointing to an unfilled price gap from early July 2024.<stembedurl>https://stocktwits.com/opportoni/message/641304712</stembedurl>Another user described the stock as “pure gold.”<stembedurl>https://stocktwits.com/piratepotatoman/message/641299736</stembedurl><a href="https://stocktwits.com/symbol/ARDX">Ardelyx’s stock</a> has risen 31% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance

The updated outlook implies Ardelyx’s lead therapy could reach $1 billion in annual revenue about four years earlier than previously expected.

Equity

<ul class="summary-bullets"><li>Ibsrela achieved $274 million in revenue in 2025, representing 73% growth vs. 2024</li><li>The company expects 2029 IBSRELA revenue to be $1 billion.&nbsp;</li><li>It expects Ibsrela FY2026 revenue to be between $410 and $430 million, up 50% from 2025.&nbsp;</li></ul>Shares of Ardelyx rallied on Thursday after it announced its preliminary guidance for the fiscal year 2026 that buoyed retail traders.&nbsp;The company said that majority of its full-year 2026 revenue will come from its &nbsp;drug Ibsrela, a first-in-class therapy for irritable bowel syndrome with constipation. It expects revenue to be between $410 and $430 million, representing growth of at least 50% compared to 2025.The company said it expects its full-year 2026 Xphozah revenue is expected to be between $110 and $120 million. Ardelyx’s Xphozah is a FDA-approved drug that is given to lower phosphorus levels in adults with chronic kidney disease on dialysis.&nbsp;“We enter 2026 exceptionally well positioned to deliver significant growth and long-term value creation as we invest in our business to accelerate our commercial opportunities,” said Mike Raab, president and chief executive officer at Ardelyx.&nbsp;Shares in the company soared nearly 17% at the time of writing.&nbsp;<h2 class="st-heading-2">Ibsrela Potential</h2>Ardelyx launched Ibsrela in the U.S. in 2022 and has since been a success for the company. The company expects 2029 Ibsrela revenue to be $1 billion.&nbsp;The drug generated a revenue of about $87 million in the fourth quarter of 2025 compared to $53.8 million in the year-ago quarter. Ibsrela finished 2025 with full year revenue totaling approximately $274 million, 73% growth compared to 2024, it said.&nbsp;It also said that a late-stage clinical trial evaluating Ibsrela in patients with chronic idiopathic constipation (CIC) has commenced and is expected to be completed in the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ARDX trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said the company is going to ‘overachieve’ in 2026.&nbsp;<a href="https://stocktwits.com/Bfunk17/message/641220312">https://stocktwits.com/Bfunk17/message/641220312</a>Another user said that their portfolio saw a big bounce due to the recent announcement.<a href="https://stocktwits.com/elisworld/message/641225054">https://stocktwits.com/elisworld/message/641225054</a>Shares of Ardenyx are up nearly 26% over the past year.&nbsp; &nbsp;

Ardelyx Stock Is Rallying – What Is Making Retail So Bullish?

The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue. 

Ardelyx (NASDAQ:ARDX) Shares Gap Up - Still a Buy?

Ardelyx (NASDAQ:ARDX) Shares Gap Up - Still a Buy...

Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ardelyx (NASDAQ:ARDX) Shares Down 6.9% - Here's Why

Ardelyx (NASDAQ:ARDX) Stock Price Down 6.9% - Here's Why...

Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?

Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Squarepoint Ops LLC Takes $708,000 Position in Ardelyx, Inc. $ARDX

Squarepoint Ops LLC acquired a new position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.02	--	--	N/A
Q3 '25	-$0.06	$0.00	100.00%	BEAT
Q2 '25	-$0.13	-$0.08	39.27%	BEAT
Q1 '25	-$0.11	-$0.17	-51.98%	MISSED
Q4 '24	$0.01	$0.02	83.86%	BEAT

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ARDX News

ARDXArdelyx Inc